Avrobio reports Q1 EPS (72c), consensus (72c)
"2019 is off to a strong start as we advance our pipeline of gene therapies for lysosomal storage diseases on multiple fronts. We expect to exit this year with three gene therapy programs in clinical trials - for Fabry, Gaucher and cystinosis," commented CEO Geoff MacKay. "Underpinning this progress is plato, AVROBIO's proprietary platform for developing, manufacturing, and commercializing our gene therapy programs globally, which we plan to utilize initially in our Company-sponsored clinical trials in Fabry and Gaucher. Our highest priority in early 2019 was to secure regulatory clearances that enable the use of plato in multiple trials in multiple countries, namely in Australia, Canada and the U.S. We believe that the plato platform, which is designed to enable the treatment of thousands of patients, if our gene therapies are approved, represents a significant advance toward commercial readiness."